Back to Search Start Over

Lenvatinib: Hyperbilirubinaemia and death: 2 case reports.

Lenvatinib: Hyperbilirubinaemia and death: 2 case reports.

Source :
Reactions Weekly. 5/9/2020, Vol. 1803 Issue 1, p152-152. 1p.
Publication Year :
2020

Abstract

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a retrospective multicenter study involving 41 patients conducted between April 2018 and October 2018 in Japan, 2 patients were described who developed hyperbilirubinaemia (one patient) and died (one patient) during treatment with lenvatinib for advanced non-resectable hepatocellular carcinoma. However, one patient developed hyperbilirubinaemia requiring treatment discontinuation within 2 weeks of therapy initiation [ I outcome not stated i ]. The other patient died within 8 weeks of therapy initiation [ I immediate cause of death not stated i ]. [Extracted from the article]

Details

Language :
English
ISSN :
01149954
Volume :
1803
Issue :
1
Database :
Academic Search Index
Journal :
Reactions Weekly
Publication Type :
Periodical
Accession number :
143153620
Full Text :
https://doi.org/10.1007/s40278-020-78346-4